Browsing Tag
GT Biopharma
2 posts
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
NK cell immunotherapy moves toward solid tumors as GT Biopharma files IND for GTB-5550 TriKE
Find out how NK cell immunotherapy is moving into solid tumors as GT Biopharma files an IND for its B7-H3-targeted TriKE GTB-5550.